AI-generated analysis. Always verify with the original filing.
Enlivex Ltd. reported full-year 2025 net income of $1.23 billion and diluted EPS of $25.48, driven by appreciation in treasury and treasury-related derivative assets totaling $2.31 billion as of December 31, 2025. This reflects the company's dual strategy in quality longevity therapeutics and prediction markets treasury, enhancing shareholder value through unrealized gains.
Event Type
Disclosure
Voluntary
Variant
6-K
Current Report on Form 6-K
| Metric | Value | Basis |
|---|---|---|
| Net Income | $1.23 | |
| Diluted Earnings Per Share (EPS) | $25.48 |